Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Tibes, Raoul ^a   Mesa, Ruben A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Hedgehog pathway inhibitors; Janus kinase inhibitors; Myelofibrosis; Targeted therapy

Indexed keywords

BCR ABL PROTEIN; BMS 833923; CYCLIN D1; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; PF 04449913; RUXOLITINIB; SONIC HEDGEHOG PROTEIN; SONIDEGIB; STAT PROTEIN; VISMODEGIB;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; CARCINOGENESIS; GENE MUTATION; GENETIC TRANSCRIPTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HUMAN; MOLECULARLY TARGETED THERAPY; MYELOFIBROSIS; NONHUMAN; PALLIATIVE THERAPY; PARACRINE SIGNALING; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; SPLENOMEGALY; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; HEMATOLOGIC NEOPLASMS; METABOLISM; PRIMARY MYELOFIBROSIS;

ANIMALS; DISEASE MODELS, ANIMAL; HEDGEHOG PROTEINS; HEMATOLOGIC NEOPLASMS; HUMANS; JANUS KINASE 2; MOLECULAR TARGETED THERAPY; PRIMARY MYELOFIBROSIS; SIGNAL TRANSDUCTION;

EID: 84898922484     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-7-18     Document Type: Review

References (113)

1. Myeloproliferative disorders. Levine RL, Gilliland DG, Blood 2008 112 2190 2198 10.1182/blood-2008-03-077966 18779404
2. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, Dupriez B, Levine RL, Passamonti F, Gotlib J, Reilly JT, Vannucchi AM, Hanson CA, Solberg LA, Orazi A, Tefferi A, International Working Group for Myelofibrosis Research and Treatment (IWG-MRT), Leukemia 2008 22 437 438 10.1038/sj.leu.2404914 17728787 (Pubitemid 351250553)
3. Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms. Tibes R, Bogenberger JM, Benson KL, Mesa RA, Mol Diagn Ther 2012 16 269 283 10.1007/s40291-012-0006-3 23023734
4. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, Tan AD, Atherton PJ, Sloan JA, Tefferi A, Cancer 2007 109 68 76 10.1002/cncr.22365 17123268 (Pubitemid 46120195)
5. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Tefferi A, Am J Hematol 2013 88 141 150 10.1002/ajh.23384 23349007
6. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A, Blood 2009 113 2895 2901 10.1182/blood-2008-07-170449 18988864
7. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CN, Radia D, Mesa RA, Blood 2011 118 401 408 10.1182/blood-2011-01- 328955 21536863
8. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A, Blood 2005 105 973 977 15388582 (Pubitemid 40170863)
9. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Tefferi A, Leukemia 2010 24 1128 1138 10.1038/leu.2010.69 20428194
10. Role of additional novel therapies in myeloproliferative neoplasms. Fiskus W, Ganguly S, Kambhampati S, Bhalla KN, Hematol Oncol Clin North Am 2012 26 959 980 10.1016/j.hoc.2012.07.001 23009932
11. Somatic mutations of calreticulin in myeloproliferative neoplasms. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schonegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R, N Engl J Med 2013 369 2379 2390 10.1056/NEJMoa1311347 24325356
12. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, et al. N Engl J Med 2013 369 2391 2405 10.1056/NEJMoa1312542 24325359
13. Mutations and prognosis in primary myelofibrosis. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, Finke C, Score J, Gangat N, Mannarelli C, Ketterling RP, Rotunno G, Knudson RA, Susini MC, Laborde RR, Spolverini A, Pancrazzi A, Pieri L, Manfredini R, Tagliafico E, Zini R, Jones A, Zoi K, Reiter A, Duncombe A, Pietra D, Rumi E, Cervantes F, Barosi G, Cazzola M, et al. Leukemia 2013 27 1861 1869 10.1038/leu.2013.119 23619563
14. Dipss plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A, J Clin Oncol 2011 29 392 397 10.1200/JCO.2010.32.2446 21149668
15. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A, Leuk Res 2009 33 1199 1203 10.1016/j.leukres.2009.01.035 19250674
16. Recent developments in myelofibrosis. Tibes R, Bogenberger JM, Mesa RA, Blood Lymphat Cancer: Targets Ther 2012 2 125 136
17. JAK2 inhibitors in the treatment of myeloproliferative neoplasms. Tibes R, Bogenberger JM, Geyer HL, Mesa RA, Expert Opin Investig Drugs 2012 21 1755 1774 10.1517/13543784.2012.721352 22991927
18. Outcome of transplantation for myelofibrosis. Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kroger N, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Schiller G, Schouten HC, Roy V, Wiernik PH, Horowitz MM, Giralt SA, Arora M, Biol Blood Marrow Transplant 2010 16 358 367 10.1016/j.bbmt.2009.10.025 19879949
19. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the chronic leukemia working party of the European group for blood and marrow transplantation. Kröger N, Holler E, Kobbe G, Bornhäuser M, Schwerdtfeger R, Baurmann H, Nagler A, Bethge W, Stelljes M, Uharek L, Wandt H, Burchert A, Corradini P, Schubert J, Kaufmann M, Dreger P, Wulf GG, Einsele H, Zabelina T, Kvasnicka HM, Thiele J, Brand R, Zander AR, Niederwieser D, de Witte TM, Blood 2009 114 5264 5270 10.1182/blood-2009-07-234880 19812383
20. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Cervantes F, Alvarez-Larrán A, Hernández-Boluda JC, Sureda A, Torrebadell M, Montserrat E, Br J Haematol 2004 127 399 403 10.1111/j.1365-2141.2004.05229.x 15521916 (Pubitemid 39536591)
21. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Barosi G, Elliott M, Canepa L, Ballerini F, Piccaluga PP, Visani G, Marchetti M, Pozzato G, Zorat F, Tefferi A, Leuk Lymphoma 2002 43 2301 2307 10.1080/1042819021000040008 12613516 (Pubitemid 35386152)
22. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, Wiseman G, Gray LA, Schroeder G, Reeder T, Zeldis JB, Tefferi A, Blood 2003 101 2534 2541 10.1182/blood-2002-09- 2928 12517815 (Pubitemid 36857609)
23. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM, Blood 2006 108 1158 1164 10.1182/blood-2006-02-004572 16609064 (Pubitemid 44232010)
24. Danazol treatment of idiopathic myelofibrosis with severe anemia. Cervantes F, Hernández-Boluda JC, Alvarez A, Nadal E, Montserrat E, Haematologica 2000 85 595 599 10870115 (Pubitemid 30450938)
25. Lenalidomide and prednisone for primary and post polycythemia vera/essential thrombocythemia myelofibrosis (MF): an Eastern Cooperative Oncology Group (ECOG) phase II trial [abstract]. Mesa RA, Yao X, Cripe LD, Li CY, Tefferi A, Tallman MS, Blood 2008 112 1753
26. Long-term outcome of pomalidomide therapy in myelofibrosis. Begna KH, Pardanani A, Mesa R, Litzow MR, Hogan WJ, Hanson CA, Tefferi A, Am J Hematol 2012 87 66 68 10.1002/ajh.22233 22081489
27. International Working Group for Myelofibrosis Research and Treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Thapaliya P, Tefferi A, Pardanani A, Steensma DP, Camoriano J, Wu W, Geyer S, Mesa RA, Am J Hematol 2011 86 96 98 10.1002/ajh.21892 21132732
28. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. Quintás-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso-Ramos C, Verstovsek S, J Clin Oncol 2009 27 4760 4766 10.1200/JCO.2009.22.6548 19720904
29. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Jabbour E, Thomas D, Kantarjian H, Zhou L, Pierce S, Cortes J, Verstovsek S, Blood 2011 118 899 902 10.1182/blood-2010-12-325589 21622644
30. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Lofvenberg E, Wahlin A, Eur J Haematol 1988 41 375 381 3197824 (Pubitemid 19003754)
31. Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis. Manoharan A, Pitney WR, Scand J Haematol 1984 33 453 459 6515328 (Pubitemid 15180564)
32. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Petti MC, Latagliata R, Spadea T, Spadea A, Montefusco E, Aloe Spiriti MA, Avvisati G, Breccia M, Pescarmona E, Mandelli F, Br J Haematol 2002 116 576 581 10.1046/j.0007-1048.2001.03331.x 11849213 (Pubitemid 34178656)
33. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A, N Engl J Med 2010 363 1117 1127 10.1056/NEJMoa1002028 20843246
34. Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis [abstract]. Pardanani AD, Caramazza D, George G, Lasho TL, Hogan WJ, Litzow MR, Begna K, Hanson CA, McClure RF, Bavisotto LM, Smith G, Kowalski M, Sirhan S, Roberts AW, Gupta V, Gotlib J, Tefferi A, J Clin Oncol 2011 29 6514
35. JAKAFI prescribing information. http://www.accessdata.fda.gov/drugsatfda- docs/label/2013/202192s003lbl.pdf
36. Jakavi assessment report. European Medicines Agency: Committee for Medicinal Products for Human Use, http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Public-assessment-report/human/002464/WC500133226.pdf
37. Novartis Pharmaceuticals Canada Inc, JAKAVI Product Monograph Dorval, Quebec: Health Canada 2013 http://hc-sc.gc.ca
38. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Scott BL, Gooley TA, Sorror ML, Rezvani AR, Linenberger ML, Grim J, Sandmaier BM, Myerson D, Chauncey TR, Storb R, Buxhofer-Ausch V, Radich JP, Appelbaum FR, Deeg HJ, Blood 2012 119 2657 2664 10.1182/blood-2011-08-372904 22234678
39. Cancer Genome Project: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR, Lancet 2005 365 1054 1061 10.1016/S0140-6736(05)71142-9 15781101 (Pubitemid 40386783)
40. A gain-of-function mutation of JAK2 in myeloproliferative disorders. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC, N Engl J Med 2005 352 1779 1790 10.1056/NEJMoa051113 15858187 (Pubitemid 40570926)
41. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG, Cancer Cell 2005 7 387 397 10.1016/j.ccr.2005.03.023 15837627 (Pubitemid 40544655)
42. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W, Nature 2005 434 1144 1148 10.1038/nature03546 15793561 (Pubitemid 40663494)
43. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM, N Engl J Med 2012 366 799 807 10.1056/NEJMoa1110557 22375971
44. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G, N Engl J Med 2012 366 787 798 10.1056/NEJMoa1110556 22375970
45. Associations between improvements in myelofibrosis (MF) symptoms and quality of life measures with splenomegaly reduction in COMFORT-I: a randomized, double-blind, phase III trial of the JAK1 and JAK2 inhibitor ruxolitinib versus placebo in patients with MF [abstract]. Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano J, Deininger MW, Shields A, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Hare T, Erickson-Viitanen S, Sun W, Sandor VA, Levy RS, Kantarjian HM, Verstovskey S, Blood 2011 118 3842 10.1182/blood-2010-12-327908
46. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Tefferi A, Blood 2012 119 2721 2730 10.1182/blood-2011-11-395228 22279053
47. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, Biamonte F, Bartalucci N, Gattoni E, Lupo ML, Finazzi G, Pancrazzi A, Antonioli E, Susini MC, Pieri L, Malevolti E, Usala E, Occhini U, Grossi A, Caglio S, Paratore S, Bosi A, Barbui T, Vannucchi AM, AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators, Blood 2011 118 2069 2076 10.1182/blood-2011-01-330563 21725052
48. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Mascarenhas J, Lu M, Li T, Petersen B, Hochman T, Najfeld V, Goldberg JD, Hoffman R, Br J Haematol 2013 161 68 75 10.1111/bjh.12220 23330839
49. A phase II study of the HDAC inhibitor givinostat in combination with hydroxyurea in patients with polycythemia vera resistant to hydroxyurea monotherapy [abstract]. Rambaldi A, Finazzi G, Vannucchi AM, Martinelli V, Rodeghiero F, Nobile F, Specchia G, Pogliani EM, Olimpieri OM, Fioritoni G, Musolino C, Saglio G, Sivera P, Barosi G, Di Tollo S, Barbui T, Blood 2011 118 1748
50. Targeting hedgehog-a cancer stem cell pathway. Merchant AA, Matsui W, Clin Cancer Res 2010 16 3130 3140 10.1158/1078-0432.CCR-09-2846 20530699
51. Improved efficacy of combination of JAK2 and hedgehog inhibitors in myelofibrosis [abstract]. Bhagwat N, Keller MD, Rampal R, Koppikar P, Shank K, De Stanchina E, Rose K, Amakye D, Levine RL, Blood 2013 122 666 10.1182/blood-2012-10-461830
52. Aurora A kinase is a novel therapeutic target in the myeloproliferative neoplasms [abstract]. Goldenson B, Malinge S, Stein BL, Lasho TL, Breyfogle L, Schultz R, Yang Q, Gilles-Gendre L, Koppikar P, Abdel-Wahab O, Ebert BL, Pardanani A, Gurbuxani S, Levine RS, Mullally A, Tefferi A, Crispino JD, Blood 2013 122 109 10.1182/blood-2013-03-494039
53. Developmental roles and clinical significance of hedgehog signaling. McMahon AP, Ingham PW, Tabin CJ, Curr Top Dev Biol 2003 53 1 114 12509125 (Pubitemid 137639458)
54. The controversial role of the hedgehog pathway in normal and malignant hematopoiesis. Mar BG, Amakye D, Aifantis I, Buonamici S, Leukemia 2011 25 1665 1673 10.1038/leu.2011.143 21660044
55. Yolk-sac hematopoiesis: the first blood cells of mouse and man. Palis J, Yoder MC, Exp Hematol 2001 29 927 936 10.1016/S0301-472X(01)00669-5 11495698 (Pubitemid 32725790)
56. Properties of the earliest clonogenic hemopoietic precursors to appear in the developing murine yolk sac. Wong PM, Chung SW, Chui DH, Eaves CJ, Proc Natl Acad Sci USA 1986 83 3851 3854 10.1073/pnas.83.11.3851 3012535 (Pubitemid 16062381)
57. Indian hedgehog activates hematopoiesis and vasculogenesis and can respecify prospective neurectodermal cell fate in the mouse embryo. Dyer MA, Farrington SM, Mohn D, Munday JR, Baron MH, Development 2001 128 1717 1730 11311154 (Pubitemid 32514853)
58. Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. St-Jacques B, Hammerschmidt M, McMahon AP, Genes Dev 1999 13 2072 2086 10.1101/gad.13.16.2072 10465785 (Pubitemid 29407348)
59. Indian hedgehog signaling in extraembryonic endoderm and ectoderm differentiation in ES embryoid bodies. Maye P, Becker S, Kasameyer E, Byrd N, Grabel L, Mech Dev 2000 94 117 132 10.1016/S0925-4773(00)00304-X 10842064 (Pubitemid 30332393)
60. Hedgehog is required for murine yolk sac angiogenesis. Byrd N, Becker S, Maye P, Narasimhaiah R, St-Jacques B, Zhang X, McMahon J, McMahon A, Grabel L, Development 2002 129 361 372 11807029 (Pubitemid 34863803)
61. Smoothened mutants reveal redundant roles for Shh and Ihh signaling including regulation of L/R symmetry by the mouse node. Zhang XM, Ramalho-Santos M, McMahon AP, Cell 2001 106 781 792 11517919 (Pubitemid 32635107)
62. Indian hedgehog supports definitive erythropoiesis. Cridland SO, Keys JR, Papathanasiou P, Perkins AC, Blood Cells Mol Dis 2009 43 149 155 10.1016/j.bcmd.2009.04.004 19443245
63. Hedgehog signaling is required for adult blood stem cell formation in zebrafish embryos. Gering M, Patient R, Dev Cell 2005 8 389 400 10.1016/j.devcel.2005.01.010 15737934 (Pubitemid 40309809)
64. Ventral embryonic tissues and hedgehog proteins induce early AGM hematopoietic stem cell development. Peeters M, Ottersbach K, Bollerot K, Orelio C, de Bruijn M, Wijgerde M, Dzierzak E, Development 2009 136 2613 2621 10.1242/dev.034728 19570846
65. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on hedgehog pathway activation. Dierks C, Beigi R, Guo GR, Zirlik K, Stegert MR, Manley P, Trussell C, Schmitt-Graeff A, Landwerlin K, Veelken H, Warmuth M, Cancer Cell 2008 14 238 249 10.1016/j.ccr.2008.08.003 18772113
66. Hedgehog modulates cell cycle regulators in stem cells to control hematopoietic regeneration. Trowbridge JJ, Scott MP, Bhatia M, Proc Natl Acad Sci USA 2006 103 14134 14139 10.1073/pnas.0604568103 16968775 (Pubitemid 44452992)
67. The hedgehog receptor patched1 regulates myeloid and lymphoid progenitors by distinct cell-extrinsic mechanisms. Siggins SL, Nguyen NY, McCormack MP, Vasudevan S, Villani R, Jane SM, Wainwright BJ, Curtis DJ, Blood 2009 114 995 1004 10.1182/blood-2009-03-208330 19483124
68. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, Kwon HY, Kim J, Chute JP, Rizzieri D, Munchhof M, VanArsdale T, Beachy PA, Reya T, Nature 2009 458 776 779 10.1038/nature07737 19169242
69. Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors. Merchant A, Joseph G, Wang Q, Brennan S, Matsui W, Blood 2010 115 2391 2396 10.1182/blood-2009-09-241703 20107231
70. Gli3-mediated hedgehog inhibition in human pluripotent stem cells initiates and augments developmental programming of adult hematopoiesis. McIntyre BA, Ramos-Mejia V, Rampalli S, Mechael R, Lee JH, Alev C, Sheng G, Bhatia M, Blood 2013 121 1543 1552 10.1182/blood-2012-09-457747 23293081
71. Regulation of murine normal and stress-induced erythropoiesis by desert hedgehog. Lau CI, Outram SV, Saldana JI, Furmanski AL, Dessens JT, Crompton T, Blood 2012 119 4741 4751 10.1182/blood-2011-10-387266 22461491
72. Non-cell-autonomous hedgehog signaling promotes murine B lymphopoiesis from hematopoietic progenitors. Cooper CL, Hardy RR, Reth M, Desiderio S, Blood 2012 119 5438 5448 10.1182/blood-2011-12-397976 22517907
73. Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Gao J, Graves S, Koch U, Liu S, Jankovic V, Buonamici S, El Andaloussi A, Nimer SD, Kee BL, Taichman R, Radtke F, Aifantis I, Cell Stem Cell 2009 4 548 558 10.1016/j.stem.2009.03.015 19497283
74. Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Hofmann I, Stover EH, Cullen DE, Mao J, Morgan KJ, Lee BH, Kharas MG, Miller PG, Cornejo MG, Okabe R, Armstrong SA, Ghilardi N, Gould S, de Sauvage FJ, McMahon AP, Gilliland DG, Cell Stem Cell 2009 4 559 567 10.1016/j.stem.2009.03.016 19497284
75. Altered canonical hedgehog-gli signalling axis in pesticide-induced bone marrow aplasia mouse model. Chaklader M, Das P, Pereira JA, Chaudhuri S, Law S, Arh Hig Rada Toksikol 2012 63 271 282 23152377
76. A hedgehog- and antennapedia-dependent niche maintains Drosophila haematopoietic precursors. Mandal L, Martinez-Agosto JA, Evans CJ, Hartenstein V, Banerjee U, Nature 2007 446 320 324 10.1038/nature05585 17361183 (Pubitemid 46426149)
77. -/- repopulating cells. Kobune M, Ito Y, Kawano Y, Sasaki K, Uchida H, Nakamura K, Dehari H, Chiba H, Takimoto R, Matsunaga T, Terui T, Kato J, Niitsu Y, Hamada H, Blood 2004 104 1002 1009 10.1182/blood-2003-09-3347 15105288 (Pubitemid 39038019)
78. Gene regulatory networks controlling hematopoietic progenitor niche cell production and differentiation in the Drosophila lymph gland. Tokusumi Y, Tokusumi T, Shoue DA, Schulz RA, PLoS One 2012 7 41604 10.1371/journal.pone. 0041604 22911822
79. Nonhematopoietic cells represent a more rational target of in vivo hedgehog signaling affecting normal or acute myeloid leukemia progenitors. Boyd AL, Salci KR, Shapovalova Z, McIntyre BA, Bhatia M, Exp Hematol 2013 41 858 869 10.1016/j.exphem.2013.05.287 23747997
80. low mouse model of myelofibrosis. Zingariello M, Martelli F, Ciaffoni F, Masiello F, Ghinassi B, D'Amore E, Massa M, Barosi G, Sancillo L, Li X, Goldberg JD, Rana RA, Migliaccio AR, Blood 2013 121 3345 3363 10.1182/blood-2012-06-439661 23462118
81. Hedgehog induction of murine vasculogenesis is mediated by Foxf1 and Bmp4. Astorga J, Carlsson P, Development 2007 134 3753 3761 10.1242/dev.004432 17881493 (Pubitemid 350104384)
82. Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cells. Okabe S, Tauchi T, Tanaka Y, Katagiri S, Ohyashiki K, Stem Cells Dev 2012 21 2939 2948 10.1089/scd.2012.0016 22642671
83. Combination of ponatinib with hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia. Katagiri S, Tauchi T, Okabe S, Minami Y, Kimura S, Maekawa T, Naoe T, Ohyashiki K, Clin Cancer Res 2013 19 1422 1432 10.1158/1078-0432.CCR-12-1777 23319824
84. Targeting the hedgehog signaling pathway limits the self-renewal of BCR-ABL1 positive leukemia vells: molecular mechanisms [abstract]. Tauchi T, Katagiri S, Okabe S, Minami Y, Naoe T, Ohyashiki K, Blood 2012 120 531
85. Combination of the hedgehog pathway inhibitor LDE225 and nilotinib targets the leukemic stem cell population in chronic myeloid leukaemia [abstract]. David A, Zhang B, Ho Y, Buonamici S, Manley P, Holyoake T, Bhatia R, Copland M, Haematologica 2011 96 0521
86. Effect of treatment with hedgehog inhibitor, PF-04449913, on leukemia-initiation potential in acute myeloid leukemia cells [abstract]. Minami Y, Fukushima N, Naoe T, J Clin Oncol 2011 31 e13520
87. Self-renewal of acute lymphocytic leukemia cells is limited by the hedgehog pathway inhibitors cyclopamine and IPI-926. Lin TL, Wang QH, Brown P, Peacock C, Merchant AA, Brennan S, Jones E, McGovern K, Watkins DN, Sakamoto KM, Matsui W, PLoS One 2010 5 15262 10.1371/journal.pone.0015262 21203400
88. Modulation of leukemic stem cell self-renewal and cell fate decisions by inhibition of hedgehog signalling in human acute lymphoblastic leukemia (ALL) [abstract]. Lang F, Badura S, Ruthardt M, Rieger MA, Ottmann OG, Blood 2012 120 2578
89. Dasatinib plus SMO antagonist versus dasatinib alone for treating patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): design of CA180-363, a phase II, open-label randomized trial [abstract]. Trudel GC, Paliwal P, Lainas I, J Clin Oncol 2012 30 TPS6634
90. Vismodegib-an hedgehog pathway inhibitor induces cell death in an ALL cell line [abstract]. Alves R, Ferreira M, Guarino P, Domingues C, Leite J, Gonçalves A, Sarmento-Ribeiro A, Haematologica 2013 98 B1775
91. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Peacock CD, Wang Q, Gesell GS, Corcoran-Schwartz IM, Jones E, Kim J, Devereux WL, Rhodes JT, Huff CA, Beachy PA, Watkins DN, Matsui W, Proc Natl Acad Sci USA 2007 104 4048 4053 10.1073/pnas.0611682104 17360475 (Pubitemid 47181576)
92. Hedgehog beyond medulloblastoma and basal cell carcinoma. Teglund S, Toftgard R, Biochim Biophys Acta 1805 2010 181 208
93. Mechanisms of hedgehog pathway activation in cancer and implications for therapy. Scales SJ, de Sauvage FJ, Trends Pharmacol Sci 2009 30 303 312 10.1016/j.tips.2009.03.007 19443052
94. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Gailani MR, Stahle-Backdahl M, Leffell DJ, Glynn M, Zaphiropoulos PG, Pressman C, Unden AB, Dean M, Brash DE, Bale AE, Toftgard R, Nat Genet 1996 14 78 81 10.1038/ng0996-78 8782823 (Pubitemid 26301550)
95. Activating Smoothened mutations in sporadic basal-cell carcinoma. Xie J, Murone M, Luoh SM, Ryan A, Gu Q, Zhang C, Bonifas JM, Lam CW, Hynes M, Goddard A, Rosenthal A, Epstein EH Jr, de Sauvage FJ, Nature 1998 391 90 92 10.1038/34201 9422511 (Pubitemid 28079221)
96. Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma. Slade I, Murray A, Hanks S, Kumar A, Walker L, Hargrave D, Douglas J, Stiller C, Izatt L, Rahman N, Fam Cancer 2011 10 337 342 10.1007/s10689-010-9411-0 21188540
97. Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development. Tostar U, Malm CJ, Meis-Kindblom JM, Kindblom LG, Toftgard R, Unden AB, J Pathol 2006 208 17 25 10.1002/path.1882 16294371 (Pubitemid 43025700)
98. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, Guo GR, Veelken H, Engelhardt M, Mertelsmann R, Kelleher JF, Schultz P, Warmuth M, Nat Med 2007 13 944 951 10.1038/nm1614 17632527 (Pubitemid 47222041)
99. Canonical and noncanonical hedgehog pathway in the pathogenesis of multiple myeloma. Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, Azab AK, Foresta U, Mitsiades CS, Rossi M, Todoerti K, Molica S, Morabito F, Neri A, Tagliaferri P, Tassone P, Anderson KC, Munshi NC, Blood 2012 120 5002 5013 10.1182/blood-2011-07-368142 22821765
100. Hedgehog pathway activation in chronic myeloid leukemia. Jagani Z, Dorsch M, Warmuth M, Cell Cycle 2010 9 3449 3456 10.4161/cc.9.17.12945 20928937
101. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A, N Engl J Med 2012 366 2171 2179 10.1056/NEJMoa1113713 22670903
102. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Gajjar A, Stewart CF, Ellison DW, Kaste S, Kun LE, Packer RJ, Goldman S, Chintagumpala M, Wallace D, Takebe N, Boyett JM, Gilbertson RJ, Curran T, Clin Cancer Res 2013 19 6305 6312 10.1158/1078-0432.CCR-13-1425 24077351
103. Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Jimeno A, Weiss GJ, Miller WH Jr, Gettinger S, Eigl BJ, Chang AL, Dunbar J, Devens S, Faia K, Skliris G, Kutok J, Lewis KD, Tibes R, Sharfman WH, Ross RW, Rudin CM, Clin Cancer Res 2013 19 2766 2774 10.1158/1078-0432.CCR-12-3654 23575478
104. A phase 1, multicenter, open-Label, first-in-human, dose-escalation study of the oral hedgehog inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Rodon J, Tawbi HA, Thomas AL, Stoller R, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC, Clin Cancer Res 2014 Epub ahead of print
105. A phase 1/2 safety and preliminary efficacy study of sonidegib (LDE225), a hedgehog pathway inhibitor, in pediatric and adult patients with relapsed or refractory medulloblastoma and other solid tumors [abstract]. Kieran M, Geoerger B, Casanova M, Chisholm J, Aerts I, Bouffet E, Brandes AA, Leary SES, Sullivan M, Bailey S, Cohen K, Mason W, Kalambakas S, Deshpande P, Tai F, Hurh E, MacDonald TJ, Neuro Oncol 2013 15 068
106. Erivedge (vismodegib) Prescribing Information. 2012 http://www.cancer. gov/cancertopics/druginfo/fda-vismodegib
107. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Amakye D, Jagani Z, Dorsch M, Nat Med 2013 19 1410 1422 10.1038/nm.3389 24202394
108. Infinity stops phase 2 trials of saridegib in chondrosarcoma and myelofibrosis. http://www.reuters.com/article/2012/06/18/idUS87102+18-Jun- 2012+BW20120618
109. Phase 1 dose-escalation study of PF-04449913, an oral hedgehog (Hh) inhibitor, in patients with select hematologic malignancies [abstract]. Jamieson C, Cortes JE, Oehler V, Baccarani M, Kantarjian HM, Papayannidis C, Rice KN, Zhang X, Shaik N, Courtney R, Levin WJ, Martinelli G, Blood 2011 118 424
110. A phase I study of an oral hedgehog pathway antagonist, BMS-833923, in patients with relapsed or refractory multiple myeloma [abstract]. Huff CA, Padmanabhan S, Kelly KR, Somlo G, Camacho L, Zonder J, Fischer B, Lang L, Zhang S, Gestone T, Bennett KL, Blood 2011 118 3993
111. ClinicalTrials.gov, http://www.clinicaltrials.gov
112. Phase I trial of hedgehog pathway inhibitor GDC-0449 in patients with refractory, locally-advanced or metastatic solid tumors. Lorusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low J, Von Hoff DD, Clin Cancer Res 2011 17 2502 2511 10.1158/1078-0432.CCR-10-2745 21300762
113. Gas1 and Kif27 genes are strongly up-regulated biomarkers of hedgehog